These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9508337)

  • 21. HMB-45 staining of dysplastic nevi. Support for a spectrum of progression toward melanoma.
    Smoller BR; McNutt NS; Hsu A
    Am J Surg Pathol; 1989 Aug; 13(8):680-4. PubMed ID: 2473661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A distinctive melanocytic lesion associated with melanoma-prone dysplastic naevus syndrome: the hybrid naevus.
    Schubert C; Parwaresch R; Rudolph P
    Virchows Arch; 2001 Feb; 438(2):166-72. PubMed ID: 11253119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mast cells in melanocytic skin lesions. An immunohistochemical and quantitative study.
    Dyduch G; Okoń K; Pescarini E
    Pol J Pathol; 2011 Sep; 62(3):139-44. PubMed ID: 22102069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nucleolin protein expression in cutaneous melanocytic lesions.
    Mourmouras V; Cevenini G; Cosci E; Epistolato MC; Biagioli M; Barbagli L; Luzi P; Mannucci S; Miracco C
    J Cutan Pathol; 2009 Jun; 36(6):637-46. PubMed ID: 19515042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
    Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
    Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutaneous malignant melanoma: correlation between neovascularization and peritumor accumulation of mast cells overexpressing vascular endothelial growth factor.
    Tóth-Jakatics R; Jimi S; Takebayashi S; Kawamoto N
    Hum Pathol; 2000 Aug; 31(8):955-60. PubMed ID: 10987256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression.
    Tellez CS; Davis DW; Prieto VG; Gershenwald JE; Johnson MM; McCarty MF; Bar-Eli M
    J Invest Dermatol; 2007 Feb; 127(2):387-93. PubMed ID: 16946713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IMP-3 is a novel progression marker in malignant melanoma.
    Pryor JG; Bourne PA; Yang Q; Spaulding BO; Scott GA; Xu H
    Mod Pathol; 2008 Apr; 21(4):431-7. PubMed ID: 18204432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Morphometric, DNA, and proliferating cell nuclear antigen measurements in benign melanocytic lesions and cutaneous malignant melanoma.
    Björnhagen V; Bonfoco E; Brahme EM; Lindholm J; Auer G
    Am J Dermatopathol; 1994 Dec; 16(6):615-23. PubMed ID: 7864299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
    Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
    J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
    Fullen DR; Zhu W; Thomas D; Su LD
    J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of DNA ploidy and degree of DNA abnormality in benign and malignant melanocytic lesions of the skin using video imaging.
    Pilch H; Günzel S; Schäffer U; Tanner B; Heine M
    Cancer; 2000 Mar; 88(6):1370-7. PubMed ID: 10717619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absence of estrogen receptors in dysplastic nevi and malignant melanoma.
    Lecavalier MA; From L; Gaid N
    J Am Acad Dermatol; 1990 Aug; 23(2 Pt 1):242-6. PubMed ID: 2212119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IMP-3 expression in melanocytic lesions.
    Yu L; Xu H; Wasco MJ; Bourne PA; Ma L
    J Cutan Pathol; 2010 Mar; 37(3):316-22. PubMed ID: 19788446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of c-kit (CD117) in Spitz nevus and malignant melanoma.
    Isabel Zhu Y; Fitzpatrick JE
    J Cutan Pathol; 2006 Jan; 33(1):33-7. PubMed ID: 16441409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.
    Singh RS; Diwan AH; Zhang PS; Prieto VG
    J Cutan Pathol; 2007 Mar; 34(3):220-5. PubMed ID: 17302605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alterations of mismatch repair protein expression in benign melanocytic nevi, melanocytic dysplastic nevi, and cutaneous malignant melanomas.
    Hussein MR; Roggero E; Sudilovsky EC; Tuthill RJ; Wood GS; Sudilovsky O
    Am J Dermatopathol; 2001 Aug; 23(4):308-14. PubMed ID: 11481522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical expression of vascular endothelial growth factor (VEGF) and C-KIT in cutaneous melanocytic lesions.
    Stefanou D; Batistatou A; Zioga A; Arkoumani E; Papachristou DJ; Agnantis NJ
    Int J Surg Pathol; 2004 Apr; 12(2):133-8. PubMed ID: 15173918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD44 and variants in melanocytic skin neoplasms.
    Schaider H; Soyer HP; Heider KH; Hofmann-Wellenhof R; Zatloukal K; Smolle J; Kerl H
    J Cutan Pathol; 1998 Apr; 25(4):199-203. PubMed ID: 9609138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.